GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical: Board Approves Q2 and Half-Year FY27 Results

RESULTS ● No Immediate Change LOW RISK
📅 Filed on BSE: 10 Nov 2026, 04:59 PM IST  ·  BSE ID: f94cd472-38f4-4d3e-a178-68c9b8e10c74
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board approved its financial results for the three and six months ending September 30, 2026.
🤖 AI Summary
  • Oxygenta Pharmaceutical Board approved un-audited financial results for Q2 FY27 and half-year ended 30.09.2026.
  • The Board meeting was held on Tuesday, November 10, 2026, at 12:30 p.m. at the corporate office.
  • Limited Review Report for the quarter ended 30.09.2026 was also considered and approved by the Board.
  • The Board meeting concluded at 4:00 p.m. on November 10, 2026, as per the official intimation.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this filing.
👤
Who Is Affected
All shareholders are informed that the company's financial results for Q2 and half-year FY27 have been approved by the Board, pending public disclosure of the detailed figures.
🔍
Management Signal
The approval signals that management has completed its review and certified the un-audited financial statements for the specified period.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Release of detailed financial results for Q2 FY27 – check revenue and profitability.
Any further Board meetings for strategic decisions post-results disclosure.
Review of subsequent quarterly results for FY27 to understand business trajectory.
LOW RISK This filing is a procedural update and does not introduce new risks.
💡 Investor Takeaway
Oxygenta Pharmaceutical's Board of Directors approved the un-audited financial results for the quarter and half-year ended September 30, 2026 (Q2 FY27). The Limited Review Report for Q2 FY27 was also approved, completing a routine financial reporting step.
📅 Company Track Record
Oxygenta Pharmaceutical's Q1 FY27 revenue from operations was Rs. 3,699.69 Lakhs, with a net loss of Rs. 210.37 Lakhs for the quarter ended 30.06.2026, as per a previous filing.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was the key decision made by Oxygenta Pharmaceutical's Board on November 10, 2026?
The Board of Directors of Oxygenta Pharmaceutical Limited approved the un-audited financial results for the quarter and half-year ended September 30, 2026.
Which financial report was approved by Oxygenta Pharmaceutical's Board?
The Board approved the un-audited financial results for the quarter and half-year ended 30.09.2026, along with the Limited Review Report for the quarter ended 30.09.2026.
When did Oxygenta Pharmaceutical's Board meeting take place for the Q2 FY27 results approval?
The Board meeting was held on Tuesday, November 10, 2026, from 12:30 p.m. to 4:00 p.m.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.